Company research
ALTEROLA BIOTECH INC.
CIK 1442999Updated Sep 26, 2026
SecurityABTI · OTC · equity
Name history
JEDEDIAH RESOURCES CORP. · through Nov 19, 2010
ABTI price & chart
Loading TradingView…
OTC:ABTI on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
15-15D filing
Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 1.01, 2.01, 5.02, 7.01, 9.01
NT 10-Q filing
10-Q filing
10-Q/A filing
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 3,663Source | 12,376,963Source | 12,127,961Source | 12,773Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | — | 0Source |
| Inventory, NetUSD | 1,009Source | 986Source | 1,050Source | — |
| Assets, CurrentUSD | 3,663Source | 237,184Source | 127,961Source | 12,773Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,333,264Source | 2,281,416Source | 1,201,685Source | 402,494Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 1,382,644Source | 807,048Source | 802,633Source | 754,280Source |
| Additional Paid in CapitalUSD | 9,663,970Source | 18,927,919Source | 18,079,554Source | 987,287Source |
| Retained Earnings (Accumulated Deficit)USD | -12,416,075Source | -9,576,247Source | -7,970,510Source | -1,531,288Source |
| Stockholders' Equity Attributable to ParentUSD | -1,329,601Source | 10,095,547Source | 10,926,276Source | -389,721Source |
| Liabilities and EquityUSD | 3,663Source | 12,376,963Source | 12,127,961Source | 12,773Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 1,333,264Source | 2,127,103Source | 1,201,685Source | 402,494Source |
| Accounts Payable, CurrentUSD | 825,210Source | 611,805Source | 542,510Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 362,451Source | 254,864Source | 396,486Source | 20,244Source |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -12,416,075Source | -9,576,247Source | -7,970,510Source | 1,221,788Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | 130,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | -50,686Source | — |
| Increase (Decrease) in InventoriesUSD | -19Source | — | -1,050Source | — |
| Increase (Decrease) in Accounts PayableUSD | 221,385Source | 69,295Source | 444,131Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -1,447,088Source | -1,039,792Source | 44,344Source | 0Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | -139,799Source | — | 0Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 1,468,856Source | 1,212,159Source | -9,669Source | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 21,768Source | 32,689Source | 34,675Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 2,654Source | 8,890Source | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -28,013Source | -77,772Source | 28,622Source | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 0Source |
| Amortization of Intangible AssetsUSD | — | — | — | 0Source |
| Deferred Other Tax Expense (Benefit)USD | — | 12,409Source | — | — |
| Gain (Loss) on Disposition of Other AssetsUSD | — | — | — | 79,000Source |
| General and Administrative ExpenseUSD | 251,999Source | 68,938Source | 93,206Source | 4,477Source |
| Impairment of Intangible Assets, Finite-livedUSD | 392,278Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | 85,174Source |
| Net Income (Loss) Attributable to ParentUSD | -2,374,379Source | -1,742,457Source | -6,471,134Source | -250,511Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -250,511Source |
| Operating ExpensesUSD | 2,108,318Source | 1,896,981Source | 6,471,134Source | 329,511Source |
| Other Nonoperating Income (Expense)USD | -266,061Source | — | — | 79,000Source |
| Proceeds from Issuance of Common StockUSD | 538,324Source | 802,500Source | 5,759,250Source | — |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -2,108,318Source | -1,896,981Source | -6,471,134Source | -329,511Source |
| Other Nonoperating Income (Expense)USD | -266,061Source | — | — | 79,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | 85,174Source |
| Net Income (Loss) Attributable to ParentUSD | -2,374,379Source | -1,742,457Source | -6,471,134Source | -250,511Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | — | — | 0Source |
| Current Income Tax Expense (Benefit)USD | — | -154,524Source | — | — |
| General and Administrative ExpenseUSD | 251,999Source | 68,938Source | 93,206Source | 4,477Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -250,511Source |
| Operating ExpensesUSD | 2,108,318Source | 1,896,981Source | 6,471,134Source | 329,511Source |
| Other IncomeUSD | — | — | — | 79,000Source |
| Research and Development ExpenseUSD | 28,770Source | 46,422Source | 341,286Source | — |